Matthew Coghlan
Company: Eli Lilly & Company
Job title: Vice President & Head Incretin Portfolio Science
Seminars:
Panel Discussion: Exploring the Weight Independent Benefits of GLP-1 3:00 pm
Evaluating the impact of GLP-1s: are all observed benefits attributable to weight reduction or are other mechanisms in play? Considering how co-morbidities should be addressed from a clinical and commercial strategy perspective Clarifying uncertainties related to expanding into numerous new therapeutic areasRead more
day: Conference Day One
Chair’s Welcoming Remarks 8:45 am
day: Conference Day One